Abstract
Objective: To assess the ability of an oral supplement to increase hair growth in women with thinning hair. Design: A randomized, placebo-controlled, double-blind study. Setting: One United States clinical site. Participants: Healthy women aged 21 to 75 years with Fitzpatrick I to IV photo skin types with self-perceived thinning hair. Measurements: Subjects were randomized to treatment with the study medication (N=10) or placebo (N=5) twice daily for 180 days. A 4cm2 area of scalp was selected for hair counts performed after 90±7 and 180±7 days of treatment. The primary efficacy measure was the change in terminal and vellus hairs in each target area. The secondary measure was changes in a self-assessment questionnaire. Results: The mean (SD) number of terminal vellus hairs among placebo-treated subjects at baseline was 256.0 (24.1), remaining at 245.0 (22.4) and 242.2 (26.9) after 90 and 180 days, respectively. The mean baseline number of terminal hairs in control-treated subjects was 271.0 (24.2) increasing to 571 (65.7) and 609.6 (66.6) after 90 and 180 days, respectively (for each, p<0.001 vs. placebo). The mean number of vellus hairs among placebo-and control-treated subjects did not significantly change. Significantly more control-treated subjects perceived improvements in overall hair volume, scalp coverage, and thickness of hair body after 90 days. Additional improvement after 180 days included hair shine, skin moisture retention, and skin smoothness. No adverse events were reported. Conclusion: The oral supplement assessed in this study safely and effectively promotes significant hair growth in women with temporary hair thinning.
Androgenic alopecia or male-pattern baldness is the most common form of hair loss in men and less commonly a cause of hair loss in women. More common causes of hair loss in women include medical conditions, such as hypothyroidism; medications including oral contraceptives; nutritional deficiencies; and physiological and emotional stresses. The causes of hair loss in elderly women may be multifactorial.Among 100 adult women with diffuse hair loss in one study, probable causes were determined to be psychological stress (30%), fever (33%), abortion and delivery (21%), trauma or surgical operations (13%), and hypothyroidism (10%).4 More than 50 percent of women had more than one likely cause of hair loss while a cause could not be determined in six percent.
The effects of hair loss on self-image and self-esteem have been well documented. In one study, significantly diminished quality of life among adult men and women with various forms of hair loss was significantly correlated with symptoms of clinical depression, and the psychological impact of hair loss among women appears to be more severe than for men. Consequently, a drug therapy that will safely and effectively increase hair growth in women is highly desirable.
An oral compound consisting of proteins and glycosaminoglycans of marine origin was found to have beneficial effects on women with sun-damaged skin. The results of two studies demonstrated improvements in the appearance of sun-damaged skin and increased skin thickness and elasticity. Brittle hair and nails returned to normal after 90 days of treatment. Subsequent studies assessed the use of a similar marine extract with the addition of other natural compounds (Viviscal® Hair Nourishment System; Lifes good, Inc., Chicago, Illinois) for the treatment of androgenetic alopecia. Several six-month, randomized, controlled studies have demonstrated the efficacy of Viviscal (the product used in these studies was originally marketed under the brand name Hairgain® [Parexel Medstat AS, Lillestrøm, Norway]) for the treatment of androgenetic alopecia. Similar results were achieved in 8- and 12-month, open-label studie Since these studies enrolled men, less is known about the use of Viviscal in women with thinning hair.
The objective of this randomized, double-blind, placebo-controlled study was to test the hypothesis that the administration of this new oral supplement over a six-month period will increase hair growth in adult women with self-perceived thinning hair associated with poor diet, stress, hormonal influences, or abnormal menstrual cycles. Preliminary results of this study have been presented elsewhere.
Resource: http://www.ncbi.nlm.nih.gov
Resource: http://www.nutritionforest.com/
Objective: To assess the ability of an oral supplement to increase hair growth in women with thinning hair. Design: A randomized, placebo-controlled, double-blind study. Setting: One United States clinical site. Participants: Healthy women aged 21 to 75 years with Fitzpatrick I to IV photo skin types with self-perceived thinning hair. Measurements: Subjects were randomized to treatment with the study medication (N=10) or placebo (N=5) twice daily for 180 days. A 4cm2 area of scalp was selected for hair counts performed after 90±7 and 180±7 days of treatment. The primary efficacy measure was the change in terminal and vellus hairs in each target area. The secondary measure was changes in a self-assessment questionnaire. Results: The mean (SD) number of terminal vellus hairs among placebo-treated subjects at baseline was 256.0 (24.1), remaining at 245.0 (22.4) and 242.2 (26.9) after 90 and 180 days, respectively. The mean baseline number of terminal hairs in control-treated subjects was 271.0 (24.2) increasing to 571 (65.7) and 609.6 (66.6) after 90 and 180 days, respectively (for each, p<0.001 vs. placebo). The mean number of vellus hairs among placebo-and control-treated subjects did not significantly change. Significantly more control-treated subjects perceived improvements in overall hair volume, scalp coverage, and thickness of hair body after 90 days. Additional improvement after 180 days included hair shine, skin moisture retention, and skin smoothness. No adverse events were reported. Conclusion: The oral supplement assessed in this study safely and effectively promotes significant hair growth in women with temporary hair thinning.
Androgenic alopecia or male-pattern baldness is the most common form of hair loss in men and less commonly a cause of hair loss in women. More common causes of hair loss in women include medical conditions, such as hypothyroidism; medications including oral contraceptives; nutritional deficiencies; and physiological and emotional stresses. The causes of hair loss in elderly women may be multifactorial.Among 100 adult women with diffuse hair loss in one study, probable causes were determined to be psychological stress (30%), fever (33%), abortion and delivery (21%), trauma or surgical operations (13%), and hypothyroidism (10%).4 More than 50 percent of women had more than one likely cause of hair loss while a cause could not be determined in six percent.
The effects of hair loss on self-image and self-esteem have been well documented. In one study, significantly diminished quality of life among adult men and women with various forms of hair loss was significantly correlated with symptoms of clinical depression, and the psychological impact of hair loss among women appears to be more severe than for men. Consequently, a drug therapy that will safely and effectively increase hair growth in women is highly desirable.
An oral compound consisting of proteins and glycosaminoglycans of marine origin was found to have beneficial effects on women with sun-damaged skin. The results of two studies demonstrated improvements in the appearance of sun-damaged skin and increased skin thickness and elasticity. Brittle hair and nails returned to normal after 90 days of treatment. Subsequent studies assessed the use of a similar marine extract with the addition of other natural compounds (Viviscal® Hair Nourishment System; Lifes good, Inc., Chicago, Illinois) for the treatment of androgenetic alopecia. Several six-month, randomized, controlled studies have demonstrated the efficacy of Viviscal (the product used in these studies was originally marketed under the brand name Hairgain® [Parexel Medstat AS, Lillestrøm, Norway]) for the treatment of androgenetic alopecia. Similar results were achieved in 8- and 12-month, open-label studie Since these studies enrolled men, less is known about the use of Viviscal in women with thinning hair.
The objective of this randomized, double-blind, placebo-controlled study was to test the hypothesis that the administration of this new oral supplement over a six-month period will increase hair growth in adult women with self-perceived thinning hair associated with poor diet, stress, hormonal influences, or abnormal menstrual cycles. Preliminary results of this study have been presented elsewhere.
Resource: http://www.ncbi.nlm.nih.gov
Resource: http://www.nutritionforest.com/
No comments:
Post a Comment